
Zepbound for Teens: SURMOUNT-ADOLESCENTS Cuts BMI 18.5% (2026)
Zepbound in teens (JAMA, Nov 15, 2026): BMI fell 18.5% vs a 0.5% rise on placebo over 72 weeks, counting everyone. Side effects, Wegovy, approval.
Read the articleAuthors
Makers of MealCam
We build MealCam, an iPhone meal-pacing coach designed to make eating rhythm visible without calorie counting or food logging.

Zepbound in teens (JAMA, Nov 15, 2026): BMI fell 18.5% vs a 0.5% rise on placebo over 72 weeks, counting everyone. Side effects, Wegovy, approval.
Read the article
In REDEFINE 9 (Nov 14, 2026), lower-dose CagriSema cut weight 18.6–19.4% in 68 weeks vs 4.6% on placebo, counting everyone. How it compares with Wegovy.
Read the article
FDA, Nov 9, 2026: every GLP-1, from Ozempic to Zepbound, gets a NAION vision-loss warning. In trials: 6.4 vs 3.8 cases per 100,000 patient-years.
Read the article
Foundayo (orforglipron) cut sleep apnea events by 17 to 18 an hour vs about 5 on placebo in two 52-week ATTAIN-OSA trials (JAMA, Nov 9, 2026). How it compares.
Read the article
Retatrutide cut knee osteoarthritis pain 3.96 vs 2.12 points on placebo and weight 20.0% vs 4.6% in TRIUMPH-4 (NEJM, Nov 8, 2026). What it means, what's next.
Read the article
Pelacarsen cut Lp(a) 78% in the Lp(a)HORIZON trial (NEJM, Nov 7, 2026), but heart events were 12.3% vs 12.1% on placebo. What it means if your Lp(a) is high.
Read the article
How to Lie with Statistics by Darrell Huff, summarized: his tricks paired with real drug, food and supplement examples, plus 5 questions to check any claim.
Read the article
Viking Therapeutics Q3 2026: VK2735's Phase 3 shot trials are full and due in 2027, a pill trial began, monthly-dose data, and why launch is years away.
Read the article
A GLP-1 plateau is expected: in trials, weight loss on Wegovy and Zepbound leveled off around weeks 60–72. Why it happens and what to check before you worry.
Read the article
Regeneron's Q3 2026 earnings: $5.1B revenue, none from obesity. Its weight-loss bet is olatorepatide plus Praluent and muscle-saving trevogrumab.
Read the article
GLP-1 constipation hits 11% to 27% of people on Zepbound, Wegovy or Foundayo. Why it happens, the steps experts recommend, and the red flags to call about.
Read the article
Lilly's Q3 2026 earnings call: Zepbound and Mounjaro hit $16.1B, Foundayo $184M, and 500,000+ got Lilly drugs via Medicare's $50 Bridge. What it means.
Read the article
Stopping a GLP-1? In the STEP 1 trial, people regained about two-thirds of the weight a year after stopping semaglutide. The numbers, and a plan to make first.
Read the article
Every major weight-loss drug in the 2026 pipeline, ranked: Zepbound, Foundayo, CagriSema, retatrutide, EloraTZP and more, sorted by when you can get them.
Read the article
Glucose Revolution by Jessie Inchauspé, summarized: all 10 Glucose Goddess hacks, which ones research backs, which are overstated, and a day to copy.
Read the article
Cagrilintide vs eloralintide: eloralintide hit 20.1% weight loss at 48 weeks, cagrilintide alone 11.8% at 68 weeks. Every trial compared, plus the caveat.
Read the article
Tradipitant for GLP-1 vomiting: in Phase 3, 43% vomited vs 58.5% on placebo after one untitrated semaglutide dose. What it means and what's unknown.
Read the article
Amylin drugs explained: how the fullness hormone differs from GLP-1, why eloralintide hit 20.1% alone, and which amylin drugs, like CagriSema, come first.
Read the article
Eloralintide Phase 3: Lilly's ENLIGHTEN-10 tests it against placebo in 3,000 adults with type 2 diabetes and heart risk. What it measures and when.
Read the article
Retatrutide brand name: Retkouro and Retzoundi are real Lilly trademark filings from 2024, but Lilly hasn't named the drug. What the records show.
Read the article
Retatrutide vs Ozempic: in an 80-week head-to-head trial in type 2 diabetes, retatrutide cut weight 20.9% vs 9.4% if all stayed on treatment. What it means.
Read the article
Eating too fast on Ozempic can backfire. A classic study found slow eating raised natural GLP-1 by 41%. Why pace matters on semaglutide, plus 3 habits.
Read the article
Outlive by Peter Attia, summarized: the Four Horsemen, why fitness may matter most, the centenarian decathlon, protein, apoB, and where critics push back.
Read the article
Why you feel full faster on Zepbound: how tirzepatide slows your stomach and quiets food noise, why fullness still arrives late, and a simple check.
Read the article
The New Menopause by Dr. Mary Claire Haver, summarized: why hot flashes can last 7+ years, what changed on hormone therapy, her symptom toolkit, and its limits.
Read the article
How to eat on GLP-1s like Wegovy, Zepbound, and Foundayo: six simple rules for smaller meals, protein first, slower eating, and fewer queasy afternoons.
Read the article
The Hunger Code by Jason Fung, summarized: 3 types of hunger, the fat thermostat, his 3 Golden Rules, what studies say on fasting and GLP-1s, and its limits.
Read the article
Foundayo side effects by dose: nausea in 26–35%, quit rates, the new FDA eye (NAION) warning, the 30-day birth control rule, and when to call a doctor.
Read the article
Ultra-Processed People by Chris van Tulleken, summarized: what counts as ultra-processed food, a 10-second label test, what the studies show, and its limits.
Read the article
CagriSema vs EloraTZP: 22.7% vs 23.3% weight loss, the fair type 2 diabetes comparison, quit rates, and which amylin combo reaches pharmacies first.
Read the article
Women on CagriSema lost 25% of body weight on average in REDEFINE 1, across menopause stages. Plus what new studies show about hormone therapy and GLP-1s.
Read the article
Skinny Liver by Kristin Kirkpatrick and Ibrahim Hanouneh, summarized: the 4-week fatty liver diet plan, what newer science backs, and what changed since 2017.
Read the article
When will retatrutide be available? Lilly plans to file with the FDA in Q1 2027. The likely approval window, early access, cost, and online “reta” risks.
Read the article
EloraTZP hit up to 23.3% weight loss in Phase 2. Now AMPLIFY-1 (2,115 people) and AMPLIFY-2 take on Zepbound's drug head to head. What they test, and when.
Read the article
Foundayo vs Zepbound compared: 12.4% vs 20.9% weight loss, $149 vs $299+ a month, side effects and quit rates. A plain-English guide to pill vs shot.
Read the article
Retatrutide sleep apnea results: AHI fell about 25–34 events an hour vs 10 on placebo in two NEJM trials. What it means, the Zepbound comparison, and timing.
Read the article
Scarcity book summary in plain English: why being short on time makes a diet harder before you open the fridge, and four small fixes that build in slack.
Read the article
The Dorito Effect summary in plain English: why real food got bland, how fake flavor filled the gap, and one question to ask before you eat anything at all.
Read the article
The Circadian Code summary in plain English: Satchin Panda's eating-window rule, the mouse and human studies, where it oversells, and a sample day to copy.
Read the article
The Circadian Diabetes Code summary in plain English: the 10-hour eating rule, the studies behind it, a sample day to copy, and where the science falls short.
Read the article
Wheat Belly summary in plain English: the three big claims, the one that holds up, where scientists push back, and a seven-day wheat test you can run yourself.
Read the article
The Secret Life of Fat summary in plain English: why your body fights to keep its fat, the leptin bill after a diet, and a one-day plan that works with it.
Read the article
I tried a zero grain diet for one day. What I ate, what my glucose monitor and scale showed the next morning, and what the research says about cutting grains.
Read the article
Salt Sugar Fat summary in plain English: how food giants tune sugar, fat and salt to keep you eating, a three-minute shelf test, and where the book falls short.
Read the article
I tried the Prolon fasting mimicking diet while on a GLP-1 to break a plateau. I quit on day 3 and gained weight. What went wrong, and what to do first.
Read the article
Beat the Heart Attack Gene summary in plain English: why a normal stress test can miss artery plaque, five things to check, and where the book oversells.
Read the article
Retatrutide vs EloraTZP: 28.3% weight loss at 80 weeks vs 23.3% at 48. A plain-English comparison, the fair diabetes matchup, A1C, and side effects.
Read the article
Johann Hari’s Magic Pill explores weight-loss drugs, our food environment, and the role food plays in our lives. A plain-English summary with evidence and limits.
Read the article
Good Energy by Casey Means with Calley Means: the metabolic-health idea, the 93% statistic, glucose monitors, and everyday habits, with evidence in context.
Read the article
Michael Moss's Hooked shows how food companies shape cravings and repeated eating, with research on ultra-processed diets, addictive behavior, and industry influence.
Read the article
A plain-English summary of The Every-Other-Day Diet by Krista Varady with Bill Gottlieb: the book’s rules, later trials and practical trade-offs.
Read the article
A plain-English look at ProLon, the five-day fasting-mimicking protocol, cell renewal, and Valter Longo's research.
Read the article
A plain-English summary of The Telomere Effect by Elizabeth Blackburn and Elissa Epel: seven lessons about habits, stress, and the limits of an aging marker.
Read the article
A plain-English summary of Why We Sleep by Matthew Walker: the useful parts, the overhyped parts, and one thing to try tonight.
Read the article
A plain-English summary of How Not to Die by Dr. Michael Greger
Read the article
A visual summary of Douglas Lisle and Alan Goldhamer’s book: why cravings aren’t a character flaw, how tastes can change, and ways to make healthier choices easier.
Read the article
A visual book summary of Dr. Caldwell B. Esselstyn Jr.’s plant-based program.
Read the article
Why rushed eating is so hard to notice, why most slow-eating advice feels like homework, and how MealCam gives you a gentle cue mid-meal.
Read the article